HALO logo
halo search icon
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.
ALLO · NAS

Allogene Therapeutics, Inc.

US$1.90

Price Arrow0.01 (0.529%)
20/05/2026 04:00:01 PM
All-CompaniesAll-ConsensusFakey Shakey - LongFakey Shakey - Long (Realtime)HALO AllHALO Consensus ValueHALO Earnings MomentumHALO Momentum+1
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Allogene Therapeutics, Inc. Overview

ALLO Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Neutral

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Strong

About ALLO

icon

Telephone

1.650.457.2700

icon

Address

210 East Grand Avenue, South San Francisco, CA 94080-4811

Description

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

ALLO Price Chart

Key Stats

Market Cap

US$652.34M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.98 - 4.46

Trade Value (12mth)

US$2,400,199.00

1 week

-5.5%

1 month

-18.53%

YTD

40%

1 year

70.27%

All time high

55.00

Key Fundamentals

EPS 3 yr Growth

-63.60%

EBITDA Margin

0.00%

Operating Cashflow

-$149m

Free Cash Flow Return

-34.20%

ROIC

-43.70%

Interest Coverage

-181.00

Quick Ratio

7.90

Other Data

Shares Outstanding (Fully Diluted)

240m

HALO Sector

Healthcare

Next Company Report Date

18-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

ALLO Announcements

Latest Announcements

DateAnnouncements
14 May 26
14 May 26
14 May 26
16 April 26
16 April 26

ALLO Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-2.09-1.32-0.87locklocklock
EPS (Fully Diluted)
$locklocklocklock-2.09-1.32-0.87locklocklock
Growth
%locklocklocklock12.336.634.6locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Allogene Therapeutics, Inc. (ALLO:NAS)?
Halo FAQ
The current share price of Allogene Therapeutics, Inc. (ALLO:NAS) is USD$1.90.
What is the 52-week high share price for Allogene Therapeutics, Inc. (ALLO:NAS)?
Halo FAQ
The 52-week high share price for Allogene Therapeutics, Inc. (ALLO:NAS) is USD$4.46.
What is the 52-week low share price for Allogene Therapeutics, Inc. (ALLO:NAS)?
Halo FAQ
The 52-week low share price for Allogene Therapeutics, Inc. (ALLO:NAS) is USD$0.98.
What is the dividend yield for Allogene Therapeutics, Inc. (ALLO:NAS)?
Halo FAQ
Allogene Therapeutics, Inc. (ALLO:NAS) does not pay a dividend.
What was Allogene Therapeutics, Inc. (ALLO:NAS) last dividend payment?
Halo FAQ
Allogene Therapeutics, Inc. (ALLO:NAS) does not pay a dividend.
What is the franking level for Allogene Therapeutics, Inc. (ALLO:NAS)?
Halo FAQ
Allogene Therapeutics, Inc. (ALLO:NAS) has a franking level of 0.00%.
In which sector is Allogene Therapeutics, Inc. (ALLO:NAS) classified?
Halo FAQ
Allogene Therapeutics, Inc. (ALLO:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.